Statins do appear to cause insulin resistance and raise the risk of developing type 2 diabetes. A large meta-analysis of randomized trials found an 11% increased risk of new diabetes among statin users compared to placebo, and a major study of over 3 million U.S. Veterans found the risk was 21% to 34% higher depending on statin potency. The effect is real, dose-dependent, and well-documented, though for most people the cardiovascular benefits still outweigh this risk.
How Statins Affect Insulin and Blood Sugar
Statins work by blocking an enzyme your liver uses to make cholesterol. But that same pathway produces other molecules your cells need for normal function, including ones that help your pancreas release insulin properly. When statins suppress this pathway, several things go wrong at the cellular level.
The insulin-producing cells in your pancreas (beta cells) rely on calcium flowing into the cell to trigger insulin release. Statins interfere with the calcium channels these cells depend on, reducing the amount of insulin they can push out in response to a rise in blood sugar. Statins also disrupt the energy-producing machinery inside these cells, lowering the energy available to drive insulin secretion.
Beyond the pancreas, statins alter the structure of cell membranes by changing their cholesterol content. This reorganizes the specialized zones on the cell surface where key proteins sit, including the transporters that pull glucose out of your blood and into your muscles. When those transporters don’t work efficiently, your tissues become less responsive to insulin, which is the definition of insulin resistance.
How Much the Risk Increases
The size of the risk depends heavily on the type and dose of statin. In the U.S. Veterans study, low-potency statins raised diabetes risk by about 21%, while high-potency statins raised it by 34%. A separate analysis found that patients on high-intensity regimens had a 23% higher risk of developing type 2 diabetes compared to those on low-intensity regimens.
Individual statins carry different levels of risk. Compared to pravastatin (which has the most favorable glucose profile), atorvastatin increased diabetes risk by 22% to 25%, rosuvastatin by 18% to 42%, and simvastatin by 10% to 14%. Fluvastatin and lovastatin showed no significant increase compared to pravastatin. Pitavastatin stands apart as the only statin shown to actually improve blood sugar control rather than worsen it.
Landmark clinical trials confirm these patterns. The JUPITER trial found rosuvastatin raised new diabetes risk by 25%. The SPARCL trial found atorvastatin raised it by 37%.
What Happens to HbA1c on Statins
HbA1c, the blood test that reflects your average blood sugar over two to three months, does rise in statin users. A systematic review and meta-analysis found that in people who already had impaired blood sugar control (such as prediabetes), statins increased HbA1c by an average of 0.21 percentage points. In people with previously normal blood sugar, the increase was larger: about 1.33 percentage points. That’s a meaningful shift, potentially enough to push someone from a normal reading into a prediabetic or diabetic range.
Interestingly, the Veterans study found that statin use was not associated with a meaningful rise in random blood glucose readings, suggesting the metabolic changes may be subtle and cumulative rather than producing dramatic spikes.
Who Faces the Highest Risk
Not everyone on a statin faces the same odds of developing diabetes. The risk concentrates in people who already have metabolic warning signs. In the JUPITER trial, participants with at least one major diabetes risk factor (metabolic syndrome, obesity, fasting blood sugar above 100 mg/dL, or elevated HbA1c) saw a 28% increase in new diabetes with rosuvastatin. Those with zero risk factors saw no increase at all.
A similar pattern emerged in trials of high-dose atorvastatin: patients with two to four risk factors experienced a 24% increase in new diabetes, while those with zero to one risk factors did not. Starting fasting glucose matters too. People whose fasting blood sugar was already at or above 95 mg/dL had significantly higher odds of converting to diabetes on a statin. Among those with fasting glucose above 100 mg/dL, the conversion rate to diabetes exceeded 10% over roughly five years of atorvastatin treatment.
Older age, female sex, and higher body weight also increase susceptibility. These aren’t reasons to refuse a statin, but they are reasons to monitor blood sugar more closely after starting one.
Fitness Changes the Equation
One of the most striking findings comes from a study tracking over 300,000 patients for a median of nearly 11 years. High-intensity statin users who were in the least-fit category had a 21% higher diabetes risk compared to least-fit patients on low-intensity statins. But highly fit patients on high-intensity statins had a 47% lower diabetes risk than least-fit patients on low-intensity statins. Physical fitness didn’t just offset the statin effect; it overwhelmed it.
The protective effect of cardiorespiratory fitness held regardless of body weight or statin dose. Patients who could achieve moderate-to-high exercise capacity (roughly 8 METs or more, equivalent to jogging at a comfortable pace) saw 30% to 60% lower diabetes risk across all statin intensity levels. This is one of the clearest pieces of evidence that regular exercise is the single most effective countermeasure against statin-related blood sugar changes.
How to Manage the Risk
If you’re on a statin and concerned about blood sugar, several practical strategies can help. The most impactful is regular physical activity, which directly improves insulin sensitivity through mechanisms that work independently of whatever the statin is doing. A consistent routine of moderate aerobic exercise provides substantial protection.
Switching statin types is another option worth discussing with your prescriber. Pravastatin and pitavastatin have minimal effects on blood sugar and HbA1c, even in people with existing diabetes. Reducing the dose of a more potent statin can also help, though this needs to be balanced against your cardiovascular goals.
For people who do develop elevated blood sugar on a statin, standard diabetes management applies. Dietary changes and exercise are the foundation. If medication becomes necessary, the same drugs used for type 2 diabetes generally work well for statin-related blood sugar elevations.
Why Statins Are Still Prescribed Despite This Risk
The cardiovascular benefits of statins remain substantial enough that guidelines from the American Diabetes Association continue to recommend moderate-intensity statin therapy for people with diabetes aged 40 to 75, and even suggest considering statins for younger adults with additional heart disease risk factors. This might seem contradictory for a drug that raises diabetes risk, but the math works out in favor of treatment for most people.
A large propensity-matched study found that even when statin users developed new diabetes, their overall cardiovascular risk remained below the threshold that would have triggered a statin prescription in the first place. In other words, the heart protection statins provide is not erased by the metabolic side effect. The diabetes that statins cause tends to be mild and manageable, while the heart attacks and strokes they prevent are often life-altering or fatal.
That said, the risk is not trivial, and it scales with dose. For someone with borderline cholesterol, modest cardiovascular risk, and multiple diabetes risk factors, the calculus may favor a lower-intensity statin, a more glucose-neutral option like pitavastatin, or a closer look at whether lifestyle changes alone could achieve the needed cholesterol reduction.